Cai-Guang Yang

TL;DR: M6A sequencing reveals that knockdown of METTL3 or METTL14 induced changes in mRNA m6A enrichment and altered mRNA expression of genes with critical biological functions in GSCs, identified as promising therapeutic targets for glioblastoma.

TL;DR: Two promising FTO inhibitors are developed, namely FB23 and FB23-2, which directly bind to FTO and selectively inhibit FTO's m6A demethylase activity, suggesting that FTO is a druggable target and that targeting FTO by small-molecule inhibitors holds potential to treat AML.

TL;DR: The collective results highlight the development of functional probes of the FTO enzyme that will enable future biological studies and pave the way for the rational design of potent and specific inhibitors of FTO for use in medicine.

TL;DR: The first identification of several small-molecule inhibitors of human FTO demethylase is reported, including the most potent compound, the natural product rhein, which is neither a structural mimic of 2-oxoglutarate nor a chelator of metal ion.

TL;DR: Virtual screening and optimization of inhibitor structure is used to identify 3,6-disubstituted triazolothiadiazole compounds as inhibitors of sortase, an enzyme that incorporates surface proteins into the staphylococcal envelope that may prevent hospital-acquired S. aureus infection in high-risk patients without the side effects of antibiotics.